Monoclonal Gammopathy of Renal Significance: Hematologic Perspective | Heather Landau, MD

Monoclonal Gammopathy of Renal Significance: Hematologic Perspective | Heather Landau, MD
First U.S. CAR-T Trial for AL Amyloidosis Shows Promise | Heather Landau, MD
First U.S. CAR-T Trial for AL Amyloidosis Shows Promise | Heather Landau, MD
Real-Time Symptom Tracking for Myeloma Patients | James Berenson, MD
Real-Time Symptom Tracking for Myeloma Patients | James Berenson, MD
Long-Term Success with Talquetamab Combo Therapy | Hang Quach, MD
Long-Term Success with Talquetamab Combo Therapy | Hang Quach, MD
Dual Antibody Combo (Tec + Tal) Shows Hope for Hard-to-Treat Myeloma | Saad Usmani, MD
Dual Antibody Combo (Tec + Tal) Shows Hope for Hard-to-Treat Myeloma | Saad Usmani, MD
Talquetamab Outcomes in R/R Myeloma with Extramedullary Disease | Aimaz Afrough, MD
Talquetamab Outcomes in R/R Myeloma with Extramedullary Disease | Aimaz Afrough, MD
Nirogacestat Enhances BCMA Expression & Improves Blenrep Response? | Malin Hultcrantz, MD, PhD
Nirogacestat Enhances BCMA Expression & Improves Blenrep Response? | Malin Hultcrantz, MD, PhD
Is Adjusting Dosing The Right Approach for Frail Myeloma Patients? | Charlotte Pawlyn, PhD
Is Adjusting Dosing The Right Approach for Frail Myeloma Patients? | Charlotte Pawlyn, PhD
Maintenance Strategies Post-ASCT for High-Risk Newly Diagnosed Myeloma | Arvind Suresh, MD
Maintenance Strategies Post-ASCT for High-Risk Newly Diagnosed Myeloma | Arvind Suresh, MD
Targeting t(4; 14) Myeloma with a New Oral MMSET Inhibitor | Saad Usmani, MD
Targeting t(4; 14) Myeloma with a New Oral MMSET Inhibitor | Saad Usmani, MD
Fewer Injections, Same-Day Collection: A New Option Before Transplant | Jack Khouri, MD
Sonrotoclax Combo Shows Promise for 11;14 Myeloma | Hang Quach, MD
Fewer Injections, Same-Day Collection: A New Option Before Transplant | Jack Khouri, MD
Sonrotoclax Combo Shows Promise for 11;14 Myeloma | Hang Quach, MD
How Doctors Spot Hidden Myeloma Risks Early | Bruno Paiva, PhD